AN2 THERAPEUTICS INC (ANTX) Stock Income Statement
USA - NASDAQ:ANTX - US0373261058 - Common Stock
1.1 USD
-0.02 (-1.79%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 39.13M | 54.55M | 69.64M | 42.26M | 21.57M | |||
| Research and Development | 24.57M | 40.49M | 54.87M | 29.51M | 16.91M | |||
| Selling, General, and Administrative Expenses | 14.56M | 14.07M | 14.76M | 12.75M | 4.67M | |||
| Operating Income | -39.13M | -54.55M | -69.64M | -42.26M | -21.57M | |||
| Interest Income/Expense | 3.98M | 5.47M | null | 1.35M | 70.00K | |||
| Other Income/Expense | null | 0 | 4.90M | -50.00K | -40.00K | |||
| Non Recurring Items | null | -2.23M | null | null | null | |||
| Income Before Taxes | -37.38M | -51.32M | -64.73M | -40.96M | -21.54M | |||
| Income Tax | null | null | null | null | null | |||
| Net Income | -37.38M | -51.32M | -64.73M | -42.78M | -28.06M | |||
| EBITDA | null | undefined | undefined | undefined | undefined | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.2474 | -1.7206 | -2.7429 | -2.79 | -1.5 | |||
| Non GAAP EPS | -1.16 | -1.6400000000000001 | -2.8200000000000003 | -4.71 | null | |||
| Statistics | ||||||||
All data in USD